Aaron Kesselheim

@akesselheim

Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital

Boston
Vrijeme pridruživanja: veljača 2009.

Tweetovi

Blokirali ste korisnika/cu @akesselheim

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @akesselheim

  1. proslijedio/la je Tweet
    Poništi
  2. prije 16 sati

    6. published essay describing why the GAIN Act of 2012 was not working to promote development of more important new antibiotics in Open Forum Infectious Diseases

    Prikaži ovu nit
    Poništi
  3. prije 16 sati

    5. Ameet Sarpatwari dug into the history of the NIH Reasonable Pricing Clause, finding that there is no evidence that it suppressed government-industry commercialization of discoveries in

    Prikaži ovu nit
    Poništi
  4. prije 16 sati

    4. In a project led out of , reviewed implications of recent Supreme Court decision in Merck v Albrecht on failure-to-warn drug litigation in flagship journal

    Prikaži ovu nit
    Poništi
  5. prije 16 sati

    3. led description of changes in drug regulation and comprehensive review of trends in testing and FDA approval statistics over last 35 years in Special Communication

    Prikaži ovu nit
    Poništi
  6. prije 16 sati

    2. compared response rates (RRs) and durations of response (DORs) for cancer drugs from early trials to RCTs showing no change in RRs but higher DORs in non-RCTs -- so be careful approving drugs based on non-RCT durable response data alone

    Prikaži ovu nit
    Poništi
  7. prije 16 sati

    Busy January at so let me catch you up on some highlights: 1. Emily Jung et al reviewed 25 highest priced drugs in 2017 Medicare, finding 41% of active ingredients were approved by FDA in other forms going back many decades:

    Prikaži ovu nit
    Poništi
  8. 3. velj

    Hey look it’s Andy Reid with a hurry-up 4th quarter super bowl offense...🤦‍♂️

    Poništi
  9. 27. sij

    In this article, we predict when we could see generics of current brand name drugs if this policy was in place:

    Poništi
  10. 27. sij

    And public sector support of new drugs:

    Prikaži ovu nit
    Poništi
  11. 27. sij
    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    16. sij

    Tired: getting your study cited by other authors Wired: getting your study findings satirized by GomerBlog

    Poništi
  13. 29. pro 2019.

    Here’s the original article published last year (!) in

    Prikaži ovu nit
    Poništi
  14. 29. pro 2019.

    In depth reporting on combination drug prices featuring ex-⁦⁩ fellow ⁦⁩ and one of her many fellowship projects! Anyone interested in a fellowship? Application details on our website!

    Prikaži ovu nit
    Poništi
  15. 20. pro 2019.

    See below if you have relevant work you want to submit!

    Poništi
  16. proslijedio/la je Tweet
    12. pro 2019.

    Join us tomorrow! A conversation with and . 12:30P, amphitheater at the Harvard School of Dental Med (188 Longwood Ave) cc

    Poništi
  17. 2. pro 2019.

    Check out our course on and US prescription drug market: "Prescription Drug Regulation, Cost and Access: Current Controversies in Context." Totally free! Quizzes and activities! Special guests! Over 12,000 enrollees to date:

    Poništi
  18. 2. pro 2019.

    Knives Out: Great movie and fun to have so many pharmaceutical policy issues tied into the plot

    Poništi
  19. proslijedio/la je Tweet
    Prikaži ovu nit
    Poništi
  20. proslijedio/la je Tweet

    Thank you to our presenters Dr. Steven Lemery from FDA, Dr. Deborah Scheag from Dana-Farber, and Dr. Lisa McShane from NCI for their great talk on the challenges of precision medicine in oncology!

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·